# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from $113 to...
RBC Capital analyst Ben Hendrix maintains Tenet Healthcare (NYSE:THC) with a Outperform and raises the price target from $10...
UBS analyst A.J. Rice maintains Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from $137 to $150.
Mizuho analyst Ann Hynes reiterates Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from $118 to $130.
Truist Securities analyst David Macdonald reiterates Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from...
Stephens & Co. analyst Scott Fidel maintains Tenet Healthcare (NYSE:THC) with a Equal-Weight and raises the price target...